MTOR and interstitial lung disease: Knowing that the molecular target of everolimus is mTOR, whose phosphorylation is inhibited by the drug, we evaluated the level of phospho-m-TOR in CLAD and CTD-ILD LFs after PEG-LIP(ev), PEG-LIP(ev)-HA400kDa and everolimus alone treatment.